Case Details
- Citation: [2022] SGHC 234
- Title: Medica Singapore Pte Ltd v Chabtini Elias Georges
- Court: High Court of the Republic of Singapore (General Division)
- Suit No: Suit No 56 of 2021
- Date of Decision: 28 September 2022
- Judge: Valerie Thean J
- Plaintiff/Applicant: Medica Singapore Pte Ltd (“Medica SG”)
- Defendant/Respondent: Chabtini Elias Georges (“Mr Chabtini”)
- Legal Area: Trusts — Express trusts (certainties; intention to create trust)
- Statutes Referenced: None stated in the provided extract
- Cases Cited: [2022] SGHC 234 (as per metadata); Guy Neale and others v Nine Squares Pty Ltd [2015] 1 SLR 1097 (express trust principles)
- Judgment Length: 23 pages, 6,192 words
Summary
In Medica Singapore Pte Ltd v Chabtini Elias Georges [2022] SGHC 234, the High Court considered whether a Singapore company (Medica SG) held certain Singapore-registered trade marks on an express trust for another entity, SRS International S.P.R.L (“SRSI”). The dispute arose after Mr Chabtini—who had been a director and significant shareholder of Medica SG—arranged for transfers of the trade marks from Medica SG to an Irish company, EMA Aesthetics Limited (“EMA”). Medica SG sued Mr Chabtini for wrongful transfer and sought declarations of ownership and consequential relief.
The court’s central inquiry was narrow but legally demanding: whether an express trust existed such that Medica SG was merely a trustee holding the trade marks for SRSI. The court applied the established “three certainties” framework for express trusts—certainty of intention, certainty of subject matter, and certainty of objects—while focusing particularly on the certainty of intention. Ultimately, the court found that the pleaded and asserted trust was not established on the evidence, and it ordered Mr Chabtini to take steps to transfer the trade marks back to Medica SG (for the jurisdictions still relevant at trial) and to pay damages for the costs Medica SG incurred in reversing the transfers.
What Were the Facts of This Case?
Medica SG is a Singapore-incorporated company within the Medica Group, a business originally founded in the United Arab Emirates by Mr Chabtini and Ms Tania Akl in the late 1990s or early 2000s. Medica SG was incorporated in 2002 as part of an international expansion plan. Its business included wholesale medical equipment for aesthetic and plastic surgery, as well as wholesale cosmetic and toiletry products. At incorporation, the initial shareholders were Mr Chabtini (60%) and Mr Namir Robert Akl (“Mr Akl”) (40%), with Ms Akl later receiving Mr Akl’s shares.
Over time, Ms Virginia Seow became a shareholder and later the sole director. In 2015, Ms Akl and Mr Chabtini gifted Ms Seow shareholdings to recognise her contributions to Medica SG. Thereafter, Mr Chabtini held 48% of the shares, while Ms Akl held 32% and Ms Seow held 20%. After the dispute arose, Ms Akl sold her shares to Ms Seow. By the time of the dispute, Ms Seow held 52% and was Medica SG’s sole director, while Mr Chabtini held 48% and was formerly a director.
The trade marks at the heart of the dispute were connected to the Medica Group’s “Skin Rejuvenation Solution” brand. The “SRS Mark” was registered in Singapore in Medica SG’s name on 9 June 2006 and renewed on 18 December 2015, remaining registered until June 2026 in class 3 for cosmetic and related products. A second trade mark (the “Second Mark”) was registered in Medica SG’s name on 30 November 2015, also in class 3, with a different design and an expiry date of 30 November 2025. Both marks used the letters “srs” (with the last “s” in reverse) and the words “Skin Rejuvenation Solution”.
In 2019, products bearing the marks generated sales revenue of $281,209.22. In early 2019, EMA was incorporated in Ireland to merge various brands, including SRSI but not including Medica SG. Mr Chabtini was one of EMA’s directors. In June 2020, Mr Chabtini applied to IPOS (the Intellectual Property Office of Singapore) to register a transfer of ownership of the Second Mark to EMA. He also transferred the SRS Mark registered in Medica SG’s name in Singapore and in other jurisdictions (Hong Kong, Indonesia, Thailand, and Taiwan) to EMA. IPOS notified Medica SG of the transfer request and asked whether Medica SG objected.
Ms Seow promptly objected by email to IPOS on 26 June 2020 at 1.31pm, stating the transfer was unauthorised. Later that day, Mr Chabtini emailed IPOS at 2.43pm instructing IPOS to ignore the earlier email and asserting that he was the owner and director of Medica SG, requesting authorisation of the transfer. As a result, the Second Mark remained registered in Medica SG’s name in Singapore, but transfers were effected in some other jurisdictions. Ms Seow later discovered that registration transfers had been effected in Indonesia, Thailand, Malaysia, Hong Kong, and Taiwan. Medica SG was able to reverse the transfers in all jurisdictions except Indonesia and Taiwan.
Meanwhile, the corporate relationship deteriorated. Ms Seow and Ms Akl decided to remove Mr Chabtini as director of Medica SG, and did so at an extraordinary general meeting on 19 October 2020. Mr Chabtini did not attend, and the resolution removed him with immediate effect. He initially disputed the validity of the meeting but resigned as director on 24 October 2020.
Medica SG commenced the suit on 15 January 2021. Its claims included a declaration that it was the rightful owner of the marks, orders requiring Mr Chabtini to transfer the SRS Mark in specified jurisdictions back to Medica SG, damages for wrongful transfer, damages for loss of profits, and interest and costs. Mr Chabtini counterclaimed for outstanding salary and other debts. Shortly before trial, Medica SG admitted the counterclaim and paid $49,000 into court.
At trial, Medica SG’s case narrowed. Mr Chabtini’s defence was that SRSI was the beneficial owner of the marks. However, neither SRSI nor EMA was joined as a party. As a result, Medica SG abandoned its prayer for a declaration of ownership premised on SRSI’s beneficial ownership on the first day of trial. Further, by the time of trial, Medica SG had successfully reversed some transfers, so it sought return only in Indonesia and Taiwan. The remaining relief was essentially damages for costs incurred in reversing transfers that had been reversed, and an order requiring Mr Chabtini to take steps to transfer the SRS Mark in Indonesia and Taiwan back to Medica SG. These were granted on 9 May 2022, with interest at 5.33% from the date of the writ. Mr Chabtini appealed.
What Were the Key Legal Issues?
The sole issue for determination was whether the SRS Mark was held on trust by Medica SG for SRSI. Although the dispute involved trade mark transfers and alleged breaches of fiduciary duty as a director, the court treated the trust question as determinative. If Medica SG held the marks on an express trust for SRSI, then Mr Chabtini’s actions might be characterised differently—potentially as actions by a person acting within the rights of the beneficial owner (SRSI) rather than as a director misappropriating company property.
Conversely, if no express trust existed, Medica SG’s registered ownership would be decisive. In that scenario, Mr Chabtini’s transfer arrangements would likely constitute a breach of fiduciary duties owed as a director, and he would be liable to take steps to reverse the wrongful transfers and compensate Medica SG for expenses incurred in recovery.
Accordingly, the legal issues were framed around the requirements for an express trust in Singapore law. The court relied on the Court of Appeal’s articulation in Guy Neale and others v Nine Squares Pty Ltd [2015] 1 SLR 1097 that an express trust is created by the actual intention of the settlor, expressed by words (including use of the word “trust”) or inferred from conduct. The “three certainties”—intention, subject matter, and objects—must be present. While the subject matter (the marks) and objects (SRSI) were arguably identifiable, the case turned on whether the evidence established the necessary certainty of intention to create a trust.
How Did the Court Analyse the Issues?
The court began by restating the governing principles for express trusts. In Guy Neale, the Court of Appeal held that an express trust arises from the settlor’s actual intention, which may be evidenced by the settlor’s language or inferred from conduct. The court also emphasised that the three certainties must be satisfied: certainty of intention, certainty of subject matter, and certainty of objects. This framework is not merely formal; it requires the court to identify whether the parties’ words and conduct objectively demonstrate an intention to create enforceable trust obligations rather than a looser arrangement or commercial understanding.
On the facts, Mr Chabtini’s defence was that the marks were beneficially owned by SRSI. He asserted that the “Skin Rejuvenation Solution” brand and trade mark were created by him and his team in the 2000s. He further claimed that, because of challenges registering the SRS Mark in SRSI’s name at the time of registration in 2006, it was “understood and agreed” between him and Ms Akl that the SRS Mark would be registered in Medica SG’s name instead, and held by Medica SG on behalf of SRSI. He relied on this alleged understanding to argue that Medica SG was a trustee and SRSI the beneficial owner.
The court’s analysis therefore focused on whether there was sufficient evidence of certainty of intention. In express trust cases, the court looks for clear indications that the parties intended to create trust obligations. A mere expectation that one party will hold property for another, or a commercial arrangement that one party will use or manage property for a related business purpose, may not suffice. The court would require evidence that Medica SG was intended to be bound in a trust capacity, with enforceable duties owed to SRSI.
Although the extract provided does not include the remainder of the judgment’s evidential findings, the court’s ultimate conclusion that the trust was not established indicates that the evidence fell short of the threshold for certainty of intention. In particular, the court would have assessed whether the “understood and agreed” narrative was supported by contemporaneous documentation, consistent conduct, or clear communications at the time of registration and thereafter. Where the alleged trust is not documented and is instead reconstructed after the fact, courts are cautious to avoid converting commercial or familial arrangements into express trusts without clear proof.
The court also had to consider the practical consequences of the trust claim. Mr Chabtini’s defence depended on SRSI being the beneficial owner and on Medica SG holding the marks on trust. Yet SRSI and EMA were not joined as parties. While non-joinder does not automatically defeat a trust claim, it affects the court’s ability to make comprehensive declarations regarding beneficial ownership and the rights of third parties. The court’s approach to the pleadings and the abandonment of certain prayers reflected this procedural and substantive difficulty. The court therefore treated the trust question as the decisive issue, but it was constrained by the evidence and the parties before it.
Finally, the court’s reasoning would have tied the trust analysis back to the fiduciary duty context. Directors owe fiduciary duties to the company, including duties to act in the company’s interests and not to appropriate company property. If Medica SG was not a trustee, then the marks were company assets. Mr Chabtini’s transfer arrangements to EMA would then be inconsistent with those duties. If, however, an express trust existed, the marks would be held for SRSI, and the director’s conduct would need to be assessed against the rights of the beneficial owner. The court’s rejection of the express trust claim meant that the fiduciary duty breach analysis effectively proceeded on the basis that Medica SG was the owner.
What Was the Outcome?
The High Court granted Medica SG the remaining remedies it sought: damages of $5,850.90 for the costs incurred in reversing the transfers that Medica SG was able to reverse, and an order requiring Mr Chabtini to take steps to transfer the SRS Mark in Indonesia and Taiwan to Medica SG. Interest was awarded at 5.33% from the date of the writ.
Practically, the outcome restored Medica SG’s position as the rightful owner of the relevant trade mark rights in the jurisdictions where transfers had not been successfully reversed before trial. It also confirmed that, absent proof of an express trust, the court will treat registered ownership as reflecting the company’s beneficial entitlement for the purposes of director accountability.
Why Does This Case Matter?
This case is significant for practitioners because it illustrates the evidential rigour required to establish an express trust over identifiable assets held in a corporate name. Even where there is a plausible commercial narrative—such as a brand being created by particular individuals and later used across related companies—courts will not lightly infer an intention to create trust obligations. The “certainty of intention” requirement is often the hardest to prove, and Medica Singapore Pte Ltd v Chabtini Elias Georges reinforces that courts will scrutinise whether the alleged trust was actually intended and enforceable, rather than merely assumed.
For directors and corporate counsel, the case also underscores fiduciary risk in cross-border intellectual property arrangements. Transfers of trade marks registered in a company’s name may attract liability if the director cannot substantiate a legal basis (such as a proven trust or other proprietary entitlement) for treating the marks as belonging beneficially to someone else. The decision therefore has practical implications for corporate governance, internal authorisations, and documentation when dealing with IP assets across group entities.
From a litigation strategy perspective, the case also highlights the importance of proper party joinder where beneficial ownership is contested. If the beneficial owner is said to be a separate entity, joining that entity can be crucial to obtaining comprehensive declarations and to ensuring that the evidential record addresses the rights and obligations of all relevant stakeholders.
Legislation Referenced
- None stated in the provided extract.
Cases Cited
- Guy Neale and others v Nine Squares Pty Ltd [2015] 1 SLR 1097
Source Documents
This article analyses [2022] SGHC 234 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.